Price
$9.67
Decreased by -9.36%
Dollar Volume (20D)
90.66 K
ADR%
8.53
Earnings Report Date (estimate)
Apr 30, 24
Shares Float
48.22 M
Shares Outstanding
1.06 M
Shares Short
8.69 K
Market Cap.
10.55 M
Beta
1.68
Price / Earnings
N/A
20D Range
9.5 13.5
50D Range
5 13.5
200D Range
5 20
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Apr 30, 24 0
Increased by +100%
-0.03
Increased by +100%
Nov 13, 23 -4.6
Decreased by -5.01 K%
-0.03
Decreased by -14.79 K%
Aug 10, 23 -0.04
Increased by +96.64%
-0.04
May 11, 23 -0.27
Increased by +70.62%
-0.05
Decreased by -420.16%
Mar 30, 23 -1.38
Decreased by -69.3%
-0.05
Decreased by -2.57 K%
Nov 11, 22 -0.09
Increased by +87.55%
-0.09
Aug 18, 22 -1.19
Decreased by -28.47%
-0.14
Decreased by -779.53%
May 5, 22 -0.91
Decreased by -73.82%
-0.52
Decreased by -76.95%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 327.73 K
Decreased by -19.95%
-2.62 M
Increased by +36.29%
Decreased by -798.54%
Increased by +20.41%
Jun 30, 23 630.88 K
Increased by +244.08%
-2.68 M
Increased by +62.95%
Decreased by -424.04%
Increased by +89.23%
Mar 31, 23 500.89 K
Increased by +111.14%
-2.41 M
Increased by +58.67%
Decreased by -480.58%
Increased by +80.42%
Dec 31, 22 592.43 K
Increased by +49.04%
-3.65 M
Increased by +17.46%
Decreased by -616.38%
Increased by +44.62%
Sep 30, 22 409.42 K
Decreased by -39.97%
-4.11 M
Decreased by -14.16%
Decreased by -1 K%
Decreased by -90.16%
Jun 30, 22 183.35 K
Decreased by -81.53%
-7.22 M
Decreased by -53.97%
Decreased by -3.94 K%
Decreased by -733.5%
Mar 31, 22 237.24 K
Decreased by -71.9%
-5.82 M
Decreased by -120.63%
Decreased by -2.45 K%
Decreased by -685.12%
Dec 31, 21 397.49 K
Decreased by -78.17%
-4.42 M
Decreased by -108.2%
Decreased by -1.11 K%
Decreased by -853.64%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot"Marie"Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.